drugset / Trial / NCT05508867
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
RandomizedParallel-groupOpen-labelTreatment
Summary
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
Timeline
- Start
- 2022-10-18
- Primary completion
- 2025-09-03
- Completion
- 2026-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Comparator | Bendamustine | Small molecule | 120 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1200 mg/m2 | Intravenous |
| Subject | favezelimab/pembrolizumab | Unknown | 200 mg | Intravenous |
| Subject | favezelimab/pembrolizumab | Unknown | 800 mg | Intravenous |